FDA
-
-
-
-
-
-
-
Incannex says psilocybin program aligns with White House order
-
-
-
-
-
-
-
Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board
-
-
-
-
-
-
-
Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder
-
-
-
-
-
-
-
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
-
-
-
-
-
-
-
Incannex Healthcare (IXHL) Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X
-
-
-
-
-
-
-
Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates
-
-
-
-
-
-
-
Incannex Healthcare (IXHL) Issues Q1 Quarterly Update
-
326,690 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

